Revenue Showdown: Sanofi vs Bristol-Myers Squibb Company

Sanofi vs Bristol-Myers: A Decade of Revenue Rivalry

__timestampBristol-Myers Squibb CompanySanofi
Wednesday, January 1, 20141587900000031999000000
Thursday, January 1, 20151656000000034861000000
Friday, January 1, 20161942700000034696000000
Sunday, January 1, 20172077600000036221000000
Monday, January 1, 20182256100000035677000000
Tuesday, January 1, 20192614500000037631000000
Wednesday, January 1, 20204251800000037369000000
Friday, January 1, 20214638500000039175000000
Saturday, January 1, 20224615900000045389000000
Sunday, January 1, 20234500600000046033000000
Loading chart...

Igniting the spark of knowledge

Revenue Showdown: Sanofi vs Bristol-Myers Squibb

In the competitive landscape of the pharmaceutical industry, revenue growth is a key indicator of success. Over the past decade, Sanofi and Bristol-Myers Squibb Company have been at the forefront, showcasing impressive financial performances. From 2014 to 2023, Sanofi consistently outpaced Bristol-Myers Squibb in revenue, with an average annual revenue of approximately $37.9 billion, compared to Bristol-Myers Squibb's $30.1 billion. Notably, in 2020, Bristol-Myers Squibb experienced a significant surge, increasing its revenue by over 60% from the previous year, closing the gap with Sanofi. By 2023, both companies were neck and neck, with Sanofi slightly ahead at $46 billion. This rivalry highlights the dynamic nature of the pharmaceutical sector, where strategic innovations and market expansions play crucial roles in shaping financial trajectories.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025